[Featured Stock] Korea Union Pharmaceutical, Trump Prescribes COVID-19 Plasma and Dexamethasone... Expectations for Overseas Exports

[Asia Economy Reporter Hyungsoo Park] Korea Union Pharmaceutical is showing strong performance.

As of 11:34 AM on the 7th, Korea Union Pharmaceutical is trading at 18,950 KRW, up 16.98% from the previous day.

The news that U.S. President Donald Trump received antibody treatment using plasma from Singaporean patients during his treatment for COVID-19 appears to have influenced the stock price.

Major foreign media outlets cited the report from 'Asia Science Magazine,' stating that one of the two antibody treatments administered to President Trump is REGN-COV2, which utilized blood samples from three Singaporean patients.

Asia Science Magazine reported that President Trump received a "large amount" of REGN-COV2 on the 2nd, before being admitted to Walter Reed Military Hospital. REGN-COV2, developed by the U.S. pharmaceutical company Regeneron, is an antibody treatment.

Earlier, President Trump was prescribed dexamethasone for COVID-19 treatment. On the 4th (local time), Dr. Brian Garibaldi of the presidential medical team stated, "President Trump's oxygen saturation dropped, so dexamethasone was prescribed for the first time," adding, "We plan to continue this prescription for the time being."

Previously, Korea Union Pharmaceutical succeeded in domestic production of raw materials for plasma expanders. The company plans to apply its proprietary technology not only to plasma treatments but also to the commercialization of antiviral drugs and immune protein fields in the future.

Korea Union Pharmaceutical also completed production of dexamethasone ampoule injections, which have gained attention as a COVID-19 treatment, and signed a contract with Medico Beautis Co., Ltd., a pharmaceutical agent specializing in exports to Russia, Central Asia, and European countries.

Korea Union Pharmaceutical previously produced dexamethasone-related drugs under the name Unidexa Injection but had ceased production. However, it prepared to produce the dexamethasone ampoule injection 'Unidexa Injection' from early September and completed production on the 24th.

This content was produced with the assistance of AI translation services.